Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea

Inclusion Criteria

• •Written informed consent must be obtained and documented according to the local regulatory requirements prior to beginning specific protocol procedures
• •Age of at least 18 and at most 45 years
• •Spontaneous and regular menstrual periods before study entry with FSH below 15 mlU/ml in follicular phase
• •Histologically confirmed primary breast cancer with the need for anthracycline-based chemotherapy
• •Steroid receptor (estrogen and progesterone) positive tumor (diagnosis according to hospital standard-procedures)
• •No clinical evidence of local recurrence or distant metastases. Complete staging work-up within 3 months prior to registration. All patients must have (bilateral) mammography or breast MRI, chest X-ray; other tests may be performed as clinically indicated
• •Karnofsky-Index \>80%
• •Life expectancy of at least 10 years, disregarding the diagnosis of cancer
• •Adequate organ function including normal red and white blood count, platelets, serum creatinine, bilirubin, and transaminases within normal range of the institution
• •Patients underwent standard Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-T)
• •Patients must be available for and compliant to treatment and follow-up. Patients registered on this trial must be treated and followed up at the participating center.